Enfermedad del higado graso no alcoholico

•Download as PPTX, PDF•

1 like•2,692 views

This document discusses non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic fatty liver (over 5-10% fat content) and non-alcoholic steatohepatitis (fatty liver with inflammation, cell injury, and/or fibrosis). It defines NAFLD, examines its epidemiology and etiological factors. It also explores the disease's pathophysiology, diagnosis, and treatment, drawing information from multiple sources on these topics.

ENFERMEDAD DEL HIGADO GRASO NO ALCOHOLICO Jorge Arturo Bustos Martinez Residente de segundo año medicina interna Universidad del Norte

Definición Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Definición NAFLD termino introducido por primera vez en 1980 por Ludwig Et. Al. clínica Mayo. Tradicionalmente se incluyen dos condiciones distintas: Hígado graso no alcohólico: superior al 5 al 10% del peso total. Esteatohepatitis: esteatosis, inflamación lobular, lesión del hepatocito y/o fibrosis. Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Epidemiologia Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Factores Etiológicos y Asociaciones MarcinKrawczyk Et. Al. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24 (2010) 695–708

Factores Etiológicos y Asociaciones Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Factores Etiológicos y Asociaciones John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

Fisiopatología Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Fisiopatología Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

Fisiopatología John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

Diagnostico Mayoría clínicamente asintomáticos: Dolor en cuadrante superior derecho Nauseas Otros síntomas inespecíficos. NASH a Cirrosis: Telangiectasias Eritema palmar Caputmedusae Etc. Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

Diagnostico SteatoTest: propuesto por Poynard Et. Al. VPP: 63% VPN: 93% ALT, alfa 2 macroglobulina, Apolipoproteina, Haptoglobina, BT, GGT, Colesterol, Trigliceridos, Glucosa, Edad, Sexo e IMC. FibroTest: Alfa 2 macroglobulina, Apolipoproteina, BT, GGT y ALT. VPP: 73% VPN: 90% Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

Diagnostico Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

Diagnostico MarcinKrawczyk Et. Al. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24 (2010) 695–708

Diagnostico John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

Tratamiento Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

Tratamiento John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

- Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver damage and inflammation that is similar to alcoholic liver disease but occurs in people who do not drink alcohol excessively. It is characterized by excess fat accumulation in the liver. - NAFLD is strongly associated with obesity and diabetes. Up to 75% of obese individuals and 50% of diabetics may have NAFLD. - Genetic factors like the PNPLA3 gene variant influence individual susceptibility to progressive liver disease among patients with NAFLD. Understanding genetic influences may help identify those at risk of progression.

Natural history NAFLD/NASH from Chronic Liver Disease Foundation

NAFLD

NAFLD/NASH progresses through stages from fatty liver to steatohepatitis to fibrosis and can eventually lead to cirrhosis. Studies have shown that around 10% of patients with NASH progress to fibrosis within 5 years, while 15% may develop cirrhosis. Long-term follow up studies of NAFLD patients found that around 50% had no change in their condition, while 27% developed fibrosis, 19% developed cirrhosis, and only 4% improved over periods of 1-9 years. Patients with more severe NASH had worse outcomes, with 26% developing cirrhosis and 44% dying in one study that followed patients for up to 18 years.

Non alcoholic fatty liver disease(NAFLD)

Bhavin Mandowara

Ueda2015 nafld, diabetes heart_dr.abdel-khalek

ueda2015

This document discusses the relationship between non-alcoholic fatty liver disease (NAFLD) and diabetes. It notes that over 55% of individuals with type 2 diabetes have NAFLD, and 30-45% of patients with non-alcoholic steatohepatitis (NASH) have type 2 diabetes. NAFLD is more common in obese and morbidly obese individuals, especially those with diabetes. The document explores the bidirectional relationship between NAFLD and diabetes, where each disease can worsen the other through mechanisms like insulin resistance, systemic inflammation, and mitochondrial dysfunction. It reviews potential treatment approaches for NAFLD in diabetic patients, including insulin sensitizers, DPP-4 inhibitors, and stat

Non Invasive Biomarkers in NASH (non-alcoholic steatohepatitis) Webinar Slides

Covance

This document discusses non-invasive biomarkers for non-alcoholic steatohepatitis (NASH). It provides an agenda for a meeting on this topic, including discussions of the need for non-invasive biomarkers in NASH, current and future methods for non-invasive diagnosis of NASH and liver fibrosis, leveraging genomics in biomarker development, and the strategic use of non-invasive testing in NASH drug development and clinical practice. Specific non-invasive tests are discussed, such as blood-based biomarkers, imaging techniques, and genomic and proteomic profiling methods for assessing liver fat, inflammation, fibrosis and other aspects of NASH.

GIT J Club: NAFLD.

Shaikhani.

This document discusses nonalcoholic fatty liver disease (NAFLD). It begins by explaining that NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Insulin resistance plays a key role in the metabolic abnormalities seen in NAFLD. The pathogenesis of NASH is not fully understood. Currently, there are no approved therapies, so treatment focuses on lifestyle modifications like weight loss and exercise to improve comorbidities. The prevalence of NAFLD is increasing due to the rising obesity epidemic.

Non alcoholic fatty liver disease

akifab93

Non Alcoholic Steatohepatitis

Elmuhtady Said FRCP FEBGH

Non-alcoholic steatohepatitis (NASH) is a disease where fat accumulates in the liver in people who drink little or no alcohol. It is increasingly common in Western countries, especially in obese and diabetic patients. Insulin resistance and the accumulation of fat in the liver are thought to cause liver inflammation and damage. While many patients are asymptomatic, NASH can progress to cirrhosis in some cases over many years. Weight loss through diet and exercise is the best treatment option to reduce fat in the liver.

This document discusses non-alcoholic fatty liver disease (NAFLD), which has become very common in urban populations. NAFLD ranges from simple fatty liver to non-alcoholic steatohepatitis (NASH), which is characterized by fatty changes, inflammation, and fibrosis that can progress to cirrhosis. The main causes are obesity, insulin resistance, and dyslipidemia. Weight loss and improving insulin sensitivity through diet and exercise are the primary treatment approaches. Medications like vitamin E, pioglitazone, and metformin may also provide benefits, but more research is still needed on medical therapies for NAFLD.

Non alcoholic fatty liver disease: what can we do about it?

philaberry

The document discusses NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). It notes that excess liver fat and liver injury are common, especially in adults who are obese or have diabetes. The pathogenesis involves insulin resistance and a two-hit hypothesis. Treatment options discussed include weight loss through diet/exercise or bariatric surgery, insulin sensitizers like metformin and thiazolidinediones, antioxidants like vitamin E, and statins. However, weight loss interventions are often not effective long-term and treatment options generally have weak or mixed results.

NAFLD, NASH

Shatdal Chaudhary

The document discusses non-alcoholic fatty liver disease (NAFLD), which includes a spectrum of conditions from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is strongly associated with obesity and metabolic syndrome. The prevalence of NAFLD is increasing globally and varies from 5-30% in different regions. Diagnosis requires imaging and liver biopsy. Treatment focuses on lifestyle modifications and medications to improve insulin resistance.

Evidence based management of Non Alcoholic fatty liver disease

Jayastu Senapati

Non-Alcoholic Fatty Liver Disease (NAFLD) is a growing problem, with a prevalence of 9-32% in India. The document discusses the epidemiology, diagnosis, and treatment of NAFLD. For diagnosis, it recommends using diagnostic indices along with imaging and liver tests, with biopsy as a last resort. Treatment involves lifestyle changes like exercise and diet modification as the most important non-pharmacological approach. Pharmacological options and investigational therapies are also discussed.

NAFLD

katejohnpunag

This document summarizes non-alcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is strongly associated with obesity, diabetes, and metabolic syndrome. While the pathogenesis is not fully understood, theories involve insulin resistance and interactions between the gut and liver. Diagnosis involves blood tests, ultrasound, or biopsy. Limited treatment options include weight loss, vitamin E (for NASH), and pioglitazone. Ongoing research is exploring new drug targets to treat NAFLD and prevent progression to end-stage liver disease.

Acute pancreatitis nejm 2006

Andrés Menéndez Rojas

This document summarizes an article from the New England Journal of Medicine about acute pancreatitis. It provides details on the pathogenesis, diagnosis, and management of acute pancreatitis. It discusses risk factors, causes, predictors of severe disease, and treatments including fluid resuscitation, determining the cause, imaging studies, ERCP, and predicting outcomes. Key points are that acute pancreatitis results from inappropriate activation of pancreatic enzymes, risk factors are gallstones and alcohol, and predictors of severe disease include scoring systems assessing inflammation and organ failure.

Nonalcoholic fatty liver disease in children and adolescents

joannayeh

This document summarizes a presentation on nonalcoholic fatty liver disease (NAFLD) in children and adolescents. It discusses the goals of screening and treatment of NAFLD, background information on prevalence and risk factors, and a randomized controlled trial on the effects of vitamin E and metformin for treating NAFLD in children. The trial found that neither vitamin E nor metformin was more effective than placebo in improving liver enzymes, but vitamin E showed some benefit in resolving nonalcoholic steatohepatitis (NASH) in children with baseline NASH. Overall, lifestyle changes focusing on weight loss remain the primary treatment approach for pediatric NAFLD due to lack of effective drug therapies.

Fatty Liver Disease - Kuwait

Neil Theise

The document discusses fatty liver disease, including alcoholic and non-alcoholic fatty liver disease (NAFLD). It notes that NAFLD is often associated with obesity, diabetes, dyslipidemia, and metabolic syndrome. The rising rates of obesity in the United States from 1985 to 2008 are shown. Pathological features of fatty liver disease including steatosis, steatohepatitis, and steatofibrosis are described. Sample diagnoses are provided. Special cases involving microvesicular steatosis and fatty liver in children are also mentioned.

NON ALCOHOLIC FATTY LIVER DISEASE

Dr. Haritha Sridhar

Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in the liver in the absence of excessive alcohol use. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD affects 25% of Americans and its prevalence is increasing worldwide. Risk factors include obesity, diabetes, and metabolic syndrome. Diagnosis involves blood tests and imaging, while biopsy is needed to diagnose NASH. Treatment focuses on lifestyle changes like weight loss and exercise. Medications being investigated include antioxidants, diabetes medications, cytoprotective agents, and lipid lowering drugs, but more research is still needed to determine the optimal pharmacotherapy.

Non alcoholic steatohepatitis copy

Keshri Yadav

Nonalcoholic Steatohepatitis (NASH) Review

mfabzak

An updated review on nonalcoholic steatohepatitis, epidemiology, pathology, diagnosis, treatment modalities and current clinical trials are reviewed. New England Journal of Medicine review article from November 2017 entitled "Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis" was extensively cited, please see references on the last slide (DOI: 10.1056/NEJMra1503519). This is purely for educational purposes; I do not diagnose, treat, or offer patient-specific advice by sharing these slides.

NAFLD in Children

CSN Vittal

Non-alcoholic fatty liver disease (NAFLD) is the buildup of fat in the liver not caused by alcohol. It is the most common form of chronic liver disease, affecting 10-20% of children globally. Risk factors include obesity, diabetes, and metabolic syndrome. NAFLD can progress from a harmless fat buildup (steatosis) to a serious inflammation (NASH), and eventually fibrosis and cirrhosis if not addressed. The pathogenesis involves genetic predisposition combined with environmental factors like diet, gut bacteria, and insulin resistance that together cause liver damage over time.

Nafld

Rajesh Mandal

This document discusses nonalcoholic fatty liver disease (NAFLD). It defines NAFLD and notes that it ranges from simple fatty liver (steatosis) to nonalcoholic steatohepatitis (NASH). The global prevalence of NAFLD is estimated to be 6-35% and is increasing. Risk factors include obesity, metabolic syndrome, diabetes and genetics. Diagnosis involves imaging or biopsy to identify hepatic steatosis and excluding other causes. Treatment focuses on lifestyle changes like diet and exercise as well as managing associated conditions. Medications may help but liver transplantation is sometimes needed for advanced disease.

Nafld

akifab93

alcohol, NASH, NAFLD, Significant alcohol intake, 1 drink , drink, metabolic syndrome, central obesity, dyslipidemia, hypertryglyceridemia, hypertension, diabetes mellitus, pathogenesis of NAFLD, Diagnosis of NAFLD, Diagnosis of NASH, ultrasound, fibroscan, treatment of nafld, fructose rich foods, coffee, coffee in NAFLD, Exercise, weight reduction, metformin, vitamin E, ursodeoxycholic acid, udiliv, pioglitazone, statins, pentoxyfilline

Autoimmune Pancreatitis

Apollo Hospitals

Autoimmune pancreatitis is the pancreatic manifestation of a systemic disorder that affects various organs, including the bile duct, retroperitoneum, kidney, and parotid and lacrimal glands. It represents a recently described subset of chronic pancreatitis that is immune mediated and has unique histologic, morphologic, and clinical characteristics. A hallmark of the disease is its rapid response to corticosteroid treatment. Although still a rare disease, autoimmune pancreatitis is increasingly becoming recognized clinically, leading to evolution in the understanding of its prognosis, clinical characteristics, and treatment.

Non alcoholic fatty liver disease

Akuffo Quarde

This document summarizes non-alcoholic fatty liver disease (NAFLD) from an endocrinology perspective. It defines NAFLD and related terms, discusses the pathophysiology involving insulin resistance and lipotoxicity, epidemiology as a growing global problem, challenges in diagnosis and evaluation, and currently available treatment options focusing on lifestyle modification and insulin sensitizers. Key points covered include the need for accurate definitions to classify disease subtypes, the role of the adipose tissue-liver axis in disease progression, and limitations of non-invasive testing underscoring the continued need for liver biopsy in certain cases.

Primary biliary cirrhosis and autoimmune hepatitis 20120902

Chien-Wei Su

This document summarizes a case of primary biliary cirrhosis (PBC) in a 66-year-old man who presented with intermittent pruritus for 8 years. Laboratory tests showed elevated liver enzymes and positive anti-mitochondrial antibodies, confirming the diagnosis of PBC. Liver biopsy showed features characteristic of PBC including destruction of bile duct epithelium and lymphocyte infiltration. The document then provides information on the epidemiology, risk factors, pathogenesis, natural history, diagnosis, treatment and prognosis of PBC.

Autoimmune hepatitis

Ahmed Ghany

Autoimmune hepatitis is a chronic inflammatory disease of the liver that results from an autoimmune attack against the liver cells. It was first described in the 1950s under various names before being termed autoimmune hepatitis in 1992. It predominantly affects females and is often diagnosed between ages 40-50. Treatment involves immunosuppressive medications like prednisone and azathioprine to induce remission of symptoms and liver inflammation. Relapses may occur upon withdrawing treatment, requiring retreatment with the same medications.

Rahimi management of nafld

PoursinaHakim

This document provides guidance on the management of nonalcoholic fatty liver disease (NAFLD). It recommends weight loss through diet and exercise to improve liver enzymes, insulin levels, and histology. Pharmacologic therapies discussed include vitamin E and pioglitazone for certain patients. Silymarine from milk thistle may provide benefits but requires more research. Cirrhosis from NASH should be monitored for complications like portal hypertension, and screening for hepatocellular carcinoma is important. Liver biopsy can help assess fibrosis if non-invasive measures are unclear.

Talk : NAFLD by Dr. S.P. Singh

Sanjeev Kumar

This document discusses the growing epidemic of non-alcoholic fatty liver disease (NAFLD) in India. It provides background on NAFLD and highlights several studies that estimate the prevalence of NAFLD in India ranges from 8.7% to 32% based on ultrasound and biopsy data. The risk of NAFLD is increased in Indians due to high rates of obesity, diabetes, and the metabolic syndrome. Left untreated, NAFLD can progress to cirrhosis of the liver, creating a serious future health burden. Increased public health education is needed to raise awareness of obesity risks and promote healthy lifestyles.

Update on NAFLD NASH.pptx

akankshagupta109892

This document provides an overview of current treatment and updates on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It begins with definitions of NAFLD and NASH. It then discusses the prevalence of NAFLD globally and in Asian countries. Risk factors and the pathogenesis involving the gut microbiota and a potential role in lean NASH are reviewed. Current methods for diagnosis including laboratory tests, imaging, serum biomarkers, and liver biopsy are summarized. Current treatment options including lifestyle modifications, metformin, pioglitazone, and vitamin E are mentioned. Several newer potential treatment approaches are also listed. The role of transient elastography in management is

MAFLD, a new name of an old disease

El-Sayed Tharwa

The document discusses the proposal to change the name of non-alcoholic fatty liver disease (NAFLD) to metabolic associated fatty liver disease (MAFLD). It notes that NAFLD's name does not accurately capture the metabolic nature of the disease. The name change was proposed by an international panel of experts and aims to reduce stigmatization and increase consideration of the disease. If adopted, MAFLD would be used instead of NAFLD to describe fatty liver disease associated with metabolic dysfunction. The document supports the name change as a way to properly frame the growing epidemic of this liver disease.

What's hot

Non Alcoholic Fatty Liver Disease: A New Urban Epidemic.

KETAN VAGHOLKAR

Non alcoholic fatty liver disease: what can we do about it?

philaberry

NAFLD, NASH

Shatdal Chaudhary

Evidence based management of Non Alcoholic fatty liver disease

Jayastu Senapati

NAFLD

katejohnpunag

Acute pancreatitis nejm 2006

Andrés Menéndez Rojas

Nonalcoholic fatty liver disease in children and adolescents

joannayeh

Fatty Liver Disease - Kuwait

Neil Theise

NON ALCOHOLIC FATTY LIVER DISEASE

Dr. Haritha Sridhar

Non alcoholic steatohepatitis copy

Keshri Yadav

Nonalcoholic Steatohepatitis (NASH) Review

NAFLD in Children

Nafld

Nafld

Autoimmune Pancreatitis

Apollo Hospitals

Non alcoholic fatty liver disease

Akuffo Quarde

Primary biliary cirrhosis and autoimmune hepatitis 20120902

Chien-Wei Su

Autoimmune hepatitis

Ahmed Ghany

Rahimi management of nafld

PoursinaHakim

Talk : NAFLD by Dr. S.P. Singh

Sanjeev Kumar

What's hot (20)

Non Alcoholic Fatty Liver Disease: A New Urban Epidemic.

Non alcoholic fatty liver disease: what can we do about it?

NAFLD, NASH

Evidence based management of Non Alcoholic fatty liver disease

NAFLD

Acute pancreatitis nejm 2006

Nonalcoholic fatty liver disease in children and adolescents

Fatty Liver Disease - Kuwait

NON ALCOHOLIC FATTY LIVER DISEASE

Non alcoholic steatohepatitis copy

Nonalcoholic Steatohepatitis (NASH) Review

NAFLD in Children

Nafld

Autoimmune Pancreatitis

Non alcoholic fatty liver disease

Primary biliary cirrhosis and autoimmune hepatitis 20120902

Autoimmune hepatitis

Rahimi management of nafld

Talk : NAFLD by Dr. S.P. Singh

Similar to Enfermedad del higado graso no alcoholico

Update on NAFLD NASH.pptx

akankshagupta109892

MAFLD, a new name of an old disease

El-Sayed Tharwa

NAFLD-Metabolic Syndrome- THE LINK

Vadivel Kumaran Sivasankaran

The document discusses non-alcoholic fatty liver disease (NAFLD) and its relationship to metabolic syndrome. It begins by defining NAFLD and its subtypes, including simple steatosis and non-alcoholic steatohepatitis (NASH). It then discusses the risk factors and pathophysiology of NAFLD, noting its association with obesity, diabetes, and other components of metabolic syndrome. The document outlines current diagnostic and treatment approaches for NAFLD, including lifestyle modifications involving diet, exercise and weight loss. It also discusses potential drug therapies and newer treatment strategies being explored.

NAFLD

Vadivel Kumaran Sivasankaran

NAFLD is a common liver disease affecting 10-24% of the general population globally. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) which is characterized by steatosis, lobular inflammation, and hepatocyte damage. Risk factors include obesity, diabetes, hyperlipidemia, and metabolic syndrome. Lifestyle modifications including weight loss through diet and exercise are the first-line treatment. Newer potential drug therapies target various disease mechanisms but require further study. Bariatric surgery can significantly improve or resolve NAFLD and related comorbidities in obese patients.

Crimson Publishers: Dietary Supplements as a Possible Trigger of Autoimmune H...

CrimsonGastroenterology

Introduction: Autoimmune hepatitis (AIH) etiology remains unknown, but in genetically predisposed individuals, diverse agents may trigger the disease. Herbal and drug induced AIH have been reported in recent years probable due to the increase in self-medication. More studies are necessary to define if drugs and herbal/dietary supplements unmask and induce AIH or drug-induced hepatitis with autoimmune features. Purpose: We report an autoimmune hepatitis case possibly induced by herbal/dietary supplements intake. Case-report: A 55-year-old female presented with a 15-day course of jaundice and increased aminotransferases. Immunologic panel showed antinuclear antibody titer of 1:320 and serum immunoglobulin G (IgG) level approximately 2 times the upper limit of normal. She reported regular daily ingestion of Herbalife® products for 6 months which were discontinued when symptoms began. Laboratory tests worsened despite the fact that patient had stopped supplements usage, and a liver biopsy was performed. Histology was suggestive of both AIH and drug induced liver disease. The patient fulfilled criteria for probable AIH based on the revised criteria for diagnosing autoimmune hepatitis, and improved with prednisolone and azathioprine therapy, with progressive laboratory improvement and symptoms remission. Discussion: Herbal/dietary supplements induced AIH has been previously reported, but the causality is not yet well established. Worsening of aminotransferases despite supplement suspension, histological findings and favorable response with corticosteroid treatment, supported the hypothesis of AIH induced by the used supplement. This case report aims to demonstrate the possible causality between herbal/dietary supplements and liver injury, including autoimmune hepatitis.

DILI

Mario Mondelli

Diabetes presentation nosscr 112011 san antonio 2

Law Firm

The document discusses diabetes, including: 1) Diabetes affects over 25 million Americans and is increasing, with some areas having higher rates. 2) The SSA is eliminating the diabetes listing due to advances in treatment, but complications can still be disabling. 3) Diabetes has two main types (1 and 2) and can cause many serious complications affecting multiple body systems if not properly managed.

Approach to Recurrent acute pancreatitis

Dr. Thakur Prashant Singh

This document discusses the approach to recurrent acute pancreatitis. It begins by defining recurrent acute pancreatitis as more than two attacks of acute pancreatitis without evidence of chronic pancreatitis, with more than three months between attacks. The document then discusses the epidemiology and various etiologies of recurrent acute pancreatitis including metabolic, mechanical, genetic, and idiopathic causes. It provides details on evaluation methods for recurrent acute pancreatitis such as bile microscopy, EUS, MRCP, and genetic testing. The document concludes that even after extensive evaluation, some cases remain undiagnosed and are termed idiopathic recurrent acute pancreatitis.

Common digestive concerns

Ellen Wong

This document provides an overview of common digestive concerns and their management from a naturopathic perspective. It begins with evaluating factors that contribute to digestive conditions like IBS, IBD, GERD and celiac disease. Next, it evaluates a case of diarrhea and abdominal pain in a 47-year-old female. It then reviews the epidemiology, pathophysiology and risk factors for GERD, IBS, IBD and celiac disease. Diagnostic guidelines, signs and symptoms, and assessment tools for each condition are outlined. Finally, management strategies are discussed, including lifestyle changes, natural therapies, pharmaceutical interventions, behavioral therapies and other modalities.

Common liver Disease in Primary Care Setting

ChernHaoChong

- The document discusses common liver problems encountered in primary care, including abnormal liver function tests, abnormal findings on liver ultrasound, and viral hepatitis serology interpretations. - Studies show that only a small percentage of abnormal liver function tests are actually due to liver disease, while the majority are caused by cancer, cardiovascular disease, or respiratory disease. - Non-alcoholic fatty liver disease is increasingly common in Asia, with genetic factors playing a stronger role. Screening and management of metabolic complications is important when NAFLD/NASH is identified. - Assessment for significant liver fibrosis or cirrhosis is important for high-risk NAFLD/NASH patients, while lifestyle modifications remain the first-line

Non-Alcoholic Fatty Liver Disease (NAFLD)

Sariu Ali

Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol consumption or other known liver diseases. It includes nonalcoholic fatty liver (NAFL) characterized by hepatic fat accumulation without inflammation or fibrosis, and nonalcoholic steatohepatitis (NASH) characterized by fat accumulation with inflammation and hepatocyte injury. NAFLD is strongly associated with obesity and metabolic syndrome. Lifestyle interventions including weight loss and exercise are recommended first-line treatment, while pioglitazone and vitamin E may improve liver histology in non-diabetic adults with NASH. Liver biopsy is needed to distinguish NASH from NAFL and assess fibrosis to guide management.

Diabetes and gut

Usama Ragab

Slides From Hot Topics in NASH:New Strategies for the Diagnosis of NASH.2019

hivlifeinfo

Strive Teleconf Presentation Oct11 2006

MedicineAndHealthNeurolog

This document summarizes a teleconference on diabetes and metabolic syndrome in patients hospitalized with cardiovascular disease. It discusses screening for diabetes and metabolic syndrome in hospitalized CVD patients, defines metabolic syndrome, reviews the prevalence and risk factors associated with it, and how metabolic syndrome predicts diabetes and increased cardiovascular risk. It also reviews inpatient management of hyperglycemia and metabolic syndrome.

Resolution of Metabolic Syndrome and Morbid Obesity Surgery

George S. Ferzli

This document summarizes research on the resolution of metabolic syndrome and morbid obesity through bariatric surgery procedures like Roux-en-Y gastric bypass and biliopancreatic diversion. Studies have found that both procedures effectively result in weight loss and normalization of blood glucose, lipids, blood pressure, and other metabolic markers in the majority of patients. Specifically, Roux-en-Y gastric bypass has been shown to improve markers of metabolic syndrome through changes in gastrointestinal hormones, while biliopancreatic diversion aims to limit fat and starch absorption.

WWDI Clinical Case Study Presentation-HS

Hillary Sullivan, DTR

Mr. Z, a 53-year-old male with necrotizing pancreatitis and multiple comorbidities, was admitted for 28 days with severe malnutrition evidenced by a 25-pound weight loss over 6 months. His nutrition care included initiating enteral nutrition via G-tube to improve immune function and wound healing for pressure ulcers. Multiple formula changes were needed due to intolerance. His condition declined and he was transferred with a critical prognosis and poor nutrition status despite nutrition interventions.

NAFLD

AsifGulam

Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent worldwide, affecting up to 30% of the global population. NAFLD is closely associated with obesity and type 2 diabetes. While initially characterized by excess fat accumulation in the liver (steatosis), some patients can progress to develop more severe non-alcoholic steatohepatitis (NASH) and liver fibrosis. Accurate staging of fibrosis is important for predicting outcomes but liver biopsy is invasive and not always practical. Non-invasive tests (NITs) using blood tests or imaging can help stratify patients' risk of advanced fibrosis as an alternative to biopsy. Lifestyle modifications addressing diet and exercise are recommended for managing NAFL

Chronic hepatitis

Annamaneni Vamshi

1. Chronic hepatitis represents liver inflammation that lasts at least 6 months and can range from mild and nonprogressive to severe, leading to cirrhosis. 2. Chronic hepatitis is classified by cause, grade or stage of liver damage, and different types include hepatitis B, C, NAFLD, alcoholic hepatitis, and autoimmune hepatitis. 3. Hepatitis B is further classified into phases including immune tolerant, immune clearance, and inactive or reactivation phases based on viral markers and liver damage.

Is There a Role for Surgery in the Treatment of Diabetes

George S. Ferzli

1. Bariatric surgery has been shown to significantly improve or resolve type 2 diabetes and other obesity-related conditions through mechanisms beyond just weight loss, such as changes in gut hormones. 2. Studies in animal models and humans found that bypassing parts of the small intestine can improve glucose control, independently of weight loss, through changes in hormones like GLP-1, GIP, leptin and others. 3. The mechanisms are not fully understood but likely involve bypassing the duodenum and proximal jejunum to alter gut hormone signaling and glucose metabolism.

Crimson Publishers: Celiac Disease and “Idiopathic” Portal Hypertension: A Ca...

CrimsonGastroenterology

Similar to Enfermedad del higado graso no alcoholico (20)

Update on NAFLD NASH.pptx

MAFLD, a new name of an old disease

NAFLD-Metabolic Syndrome- THE LINK

NAFLD

Crimson Publishers: Dietary Supplements as a Possible Trigger of Autoimmune H...

DILI

Diabetes presentation nosscr 112011 san antonio 2

Approach to Recurrent acute pancreatitis

Common digestive concerns

Common liver Disease in Primary Care Setting

Non-Alcoholic Fatty Liver Disease (NAFLD)

Diabetes and gut

Slides From Hot Topics in NASH:New Strategies for the Diagnosis of NASH.2019

Strive Teleconf Presentation Oct11 2006

Resolution of Metabolic Syndrome and Morbid Obesity Surgery

WWDI Clinical Case Study Presentation-HS

NAFLD

Chronic hepatitis

Is There a Role for Surgery in the Treatment of Diabetes

Crimson Publishers: Celiac Disease and “Idiopathic” Portal Hypertension: A Ca...

More from Jorge Bustos

Anatomía cardiaca

Jorge Bustos

Flipped classroom

Jorge Bustos

El documento habla sobre el modelo educativo Flipped Classroom y su potencial para mejorar la educación. Flipped Classroom invierte el aprendizaje tradicional al mover la instrucción directa fuera del aula y utilizar el tiempo de clase para el aprendizaje práctico y el trabajo en equipo. Este enfoque podría aprovechar mejor las plataformas tecnológicas para ofrecer una educación más personalizada y desarrollar un conjunto más amplio de competencias.

Sepsis, revision de tema dr corzo

Jorge Bustos

El documento resume la fisiopatología de la sepsis, incluyendo la cascada inflamatoria iniciada por la detección de patrones moleculares asociados a patógenos, la producción de citoquinas proinflamatorias y quimioquinas, y los mecanismos de regulación antiinflamatoria. También describe la participación del complemento y los efectos en la integridad endotelial y permeabilidad vascular, factores clave en la gravedad de la sepsis. Finalmente, menciona brevemente el tratamiento con terapia objetivo temprana

Trombosis venosa profunda

Jorge Bustos

Este documento resume la trombosis venosa profunda, incluyendo su fisiopatología, epidemiología, factores de riesgo, diagnóstico y tratamiento. La trombosis venosa profunda es un coágulo de sangre que se forma en las venas profundas de las piernas o en otras partes del cuerpo. El embarazo es un importante factor de riesgo. El diagnóstico incluye exámenes clínicos y de laboratorio como el dímero-D. El tratamiento principal es la anticoagulación para prevenir

Los teléfonos móviles para mejorar la practica de la neurologia

Jorge Bustos

Este documento describe cómo los teléfonos inteligentes pueden mejorar la práctica de la neurología. Explica que los teléfonos inteligentes son sucesores de los teléfonos móviles y PDAs que se conectan a Internet y tienen tiendas de aplicaciones. Detalla algunas aplicaciones generales y específicas para la salud que pueden usarse por pacientes y personal médico. Finalmente, discute desafíos como la duración de la batería y privacidad, y cómo los teléfonos inteligentes continuarán mejorando con mayor capacidad

140 usos de twitter en medicina 2010

Jorge Bustos

Twitter puede ser útil en medicina de varias maneras. Un ejemplo es cómo una mujer llamada Erin encontró la causa de su dolor de muñeca a través de Twitter y pudo comunicarse directamente con un experto, lo que la llevó a un diagnóstico y tratamiento correctos. El documento luego enumera más de 70 usos potenciales de Twitter en la medicina, como reclutamiento de donantes de órganos, estudios epidemiológicos, alertas de emergencia, educación médica y apoyo a pacientes. Concluye que Twitter puede ser una her

Hemorragia intracerebral

Jorge Bustos

La hemorragia intracerebral es una ruptura de un vaso sanguíneo dentro del cerebro que causa un derrame de sangre. Afecta a millones de personas anualmente y es una de las principales causas de discapacidad y muerte en el mundo. Los factores de riesgo incluyen la hipertensión, la angiopatía amiloide cerebral y el uso de anticoagulantes. El diagnóstico se realiza mediante TC o RM y el tratamiento consiste en control de presión arterial, hemostasia y manejo médico o quirúrgico según la

Manejo paliativo

Jorge Bustos

More from Jorge Bustos (8)

Anatomía cardiaca

Flipped classroom

Sepsis, revision de tema dr corzo

Trombosis venosa profunda

Los teléfonos móviles para mejorar la practica de la neurologia

140 usos de twitter en medicina 2010

Hemorragia intracerebral

Manejo paliativo

Enfermedad del higado graso no alcoholico

1. ENFERMEDAD DEL HIGADO GRASO NO ALCOHOLICO Jorge Arturo Bustos Martinez Residente de segundo año medicina interna Universidad del Norte

2. Definición Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

3. Definición NAFLD termino introducido por primera vez en 1980 por Ludwig Et. Al. clínica Mayo. Tradicionalmente se incluyen dos condiciones distintas: Hígado graso no alcohólico: superior al 5 al 10% del peso total. Esteatohepatitis: esteatosis, inflamación lobular, lesión del hepatocito y/o fibrosis. Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

4. Epidemiologia Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

5. Epidemiologia Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

6. Factores Etiológicos y Asociaciones MarcinKrawczyk Et. Al. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24 (2010) 695–708

7. Factores Etiológicos y Asociaciones Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

8. Factores Etiológicos y Asociaciones Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

9. Factores Etiológicos y Asociaciones Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

10. Factores Etiológicos y Asociaciones John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

11. Fisiopatología Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

12. Fisiopatología Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

13. Fisiopatología John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

14. Fisiopatología Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

15. Fisiopatología John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

16. Fisiopatología John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

17. Fisiopatología Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

18. Diagnostico Mayoría clínicamente asintomáticos: Dolor en cuadrante superior derecho Nauseas Otros síntomas inespecíficos. NASH a Cirrosis: Telangiectasias Eritema palmar Caputmedusae Etc. Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

19. Diagnostico SteatoTest: propuesto por Poynard Et. Al. VPP: 63% VPN: 93% ALT, alfa 2 macroglobulina, Apolipoproteina, Haptoglobina, BT, GGT, Colesterol, Trigliceridos, Glucosa, Edad, Sexo e IMC. FibroTest: Alfa 2 macroglobulina, Apolipoproteina, BT, GGT y ALT. VPP: 73% VPN: 90% Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

20. Diagnostico Jeffrey R. Lewis • Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update; Dig DisSci (2010) 55:560–578

21. Diagnostico MarcinKrawczyk Et. Al. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24 (2010) 695–708

22. Diagnostico MarcinKrawczyk Et. Al. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24 (2010) 695–708

23. Diagnostico John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

24. Tratamiento Vassilios A Sevastianos and Stephanos J Hadziyannis.Nonalcoholic fatty liver disease: from clinical recognition to treatment; Expert Rev. Gastroenterol. Hepatol. 2(1), 59–79 (2008)

25. Tratamiento John Edmison, MD, Arthur J. McCullough, MD. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data; Clin Liver Dis 11 (2007) 75–104

26. Gracias

Enfermedad del higado graso no alcoholico

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Enfermedad del higado graso no alcoholico

Similar to Enfermedad del higado graso no alcoholico (20)

More from Jorge Bustos

More from Jorge Bustos (8)

Enfermedad del higado graso no alcoholico